Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States.
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical safety of daily tenofovir disoproxil fumarate (TDF) among HIV-negative men who have sex with men. DESIGN: Randomized, double-blind, placebo-controlled trial. Participants were randomized 1:1:1:1 to immediate or delayed study drug (TDF, 300 mg orally per day, or placebo). METHODS: Four hundred healthy HIV-uninfected men who have sex with men reporting anal sex with another man within the previous 12 months enrolled in Atlanta, Boston, and San Francisco. HIV serostatus, clinical and laboratory adverse events (AEs), adherence (pill count, Medication Event Monitoring System, and self-report), and sexual and other sociobehavioral data were assessed at 3-month intervals for 24 months. Primary outcomes were clinical safety, assessed by incidence of AEs and laboratory abnormalities. RESULTS: Study drug was initiated by 373 (93%) participants (186 TDF and 187 placebo), of whom 325 (87%) completed the final study visit. Of 2428 AEs reported among 334 (90%) participants, 2366 (97%) were mild or moderate in severity. Frequencies of commonly reported AEs did not differ significantly between TDF and placebo arms. In multivariable analyses, back pain was more likely among TDF recipients (P = 0.04); these reports were not associated with documented fractures or other objective findings. There were no grade ≥3 creatinine elevations; grades 1 and 2 creatinine increases were not associated with TDF receipt. Estimated percentage of study drug doses taken was 92% by pill count and 77% by Medication Event Monitoring System. Seven seroconversions occurred: 4 on placebo and 3 among delayed arm participants not yet on study drug. CONCLUSIONS: Daily oral TDF was well tolerated, with reasonable adherence. No significant renal concerns were identified.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Daily oral antiretroviral PrEP with a fixed-dose combination of emtricitabine (FTC) and either tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide (TAF) have demonstrated safety (74) and a substantial reduction in the rate of HIV acquisition for MSM (75).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [74]
In the citing paper
“Studies have demonstrated that a daily oral medication TDF/FTC is effective in preventing HIV acquisition, and specifically among MSM (74,75,201).”
From Sexually Transmitted Infections Treatment Guidelines, 2021 (2021) · cites this paper as [74]
Citations
Cites
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096 · cited 1×
“Evidence for efficacy of daily oral FTC/TDF for MSM is clear on an intention to treat basis, and the reduction of HIV risk was high among those with detectable drug exposure, highlighting how the use of PrEP is a critical determinant of PrEP activity.(10) However, important questions remain that bear on feasibility, d…”
BackgroundSelf-citationAntiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256 · cited 2×
“Efficacy of this regimen was also demonstrated in young heterosexual men and women in Botswana(11) and heterosexual serodiscordant couples in Kenya and Uganda.(12) However, 2 studies conducted among heterosexually active women in several African countries (the Pre-exposure Prophylaxis Trial for HIV Prevention Among Af…”
ResultAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
Self-citationSurvival Analysis: A Self-Learning Text
Carpenter, M. (1997) · Technometrics · doi:10.1080/00401706.1997.10485091 · Cited by 1,811
Generalized Estimating Equations
Hardin, J. W., & Hilbe, J. M. (2002) · doi:10.1201/9781420035285 · Cited by 1,766
Estimated HIV Incidence in the United States, 2006–2009
Prejean, J., Song, R., Hernandez, A., Ziebell, R., Green, T., Walker, F., Lin, L. S., An, Q., Mermin, J., Lansky, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017502 · Cited by 1,071 · cited 1×
“A troubling increase in incidence has been noted among MSM, particularly young MSM of color.(4) HIV antiretroviral preexposure prophylaxis (PrEP) may become an important prevention option for some at-risk MSM.”
BackgroundFarmer, K. C. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80026-5 · Cited by 889 · cited 1×
“The adherence measures used in this study to estimate time on drug—self-report, pill count, and MEMS—each have characteristic limitations.(31) The level of adherence required for protection is unknown.”
MethodSurvival Analysis: A Self-Learning Text
Carpenter, M., & Kleinbaum, D. G. (1997) · Technometrics · doi:10.2307/1270914 · Cited by 812 · cited 3×
“Incidence of recurrent AEs was compared between groups by modeling AE count using the generalized estimating equation formulation of Poisson regression with total follow-up time as an offset variable.27 Multivariable analysis included treatment assignment as the main predictor and the following covariates: site, immed…”
MethodBuonamici, S., Williams, J., Morrissey, M., Wang, A., Guo, R., Vattay, A., Hsiao, K., Yuan, J., Green, J., Ospina, B., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001599 · Cited by 562
Patterson, K. B., Prince, H. A., Kraft, E., Jenkins, A. J., Shaheen, N. J., Rooney, J. F., Cohen, M. S., & Kashuba, A. D. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003174 · Cited by 355
Nelson, M. R., Katlama, C., Montaner, J. S., Cooper, D. A., Gazzard, B., Clotet, B., Lazzarin, A., Schewe, K., Lange, J., Wyatt, C., et al. (2007) · AIDS · doi:10.1097/qad.0b013e3280b07b33 · Cited by 352
García-Lerma, J. G., Otten, R. A., Qari, S. H., Jackson, E., Cong, M.-E., Masciotra, S., Luo, W., Kim, C., Adams, D. R., Monsour, M., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050028 · Cited by 350
Fanconi syndrome and renal failure induced by tenofovir: A first case report
Verhelst, D., Monge, M., Meynard, J.-L., Fouqueray, B., Mougenot, B., Girard, P.-M., Ronco, P., & Rossert, J. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.36924 · Cited by 349
Herlitz, L. C., Mohan, S., Stokes, M. B., Radhakrishnan, J., D'Agati, V. D., & Markowitz, G. S. (2010) · Kidney International · doi:10.1038/ki.2010.318 · Cited by 348
Smith, D. K., Grant, R. M., Weidle, P. J., Lansky, A., Mermin, J., & Fenton, K. A. (2011) · PubMed · Cited by 325
Self-citationClinically-indicated replacement versus routine replacement of peripheral venous catheters
Webster, J., Osborne, S., Rickard, C. M., & New, K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007798.pub3 · Cited by 313
Labarga, P., Barreiro, P., Martin-Carbonero, L., Rodriguez-Novoa, S., Solera, C., Medrano, J., Rivas, P., Albalater, M., Blanco, F., Moreno, V., et al. (2009) · AIDS · doi:10.1097/qad.0b013e3283262a64 · Cited by 294
Renal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases
Peyri??re, H., Reynes, J., Rouanet, I., Daniel, N., de Boever, C. M., Mauboussin, J.-M., Leray, H., Moachon, L., Vincent, D., & Salmon-C??ron, D. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00007 · Cited by 262
Subbarao, S., Otten, R. A., Ramos, A., Kim, C., Jackson, E., Monsour, M., Adams, D. R., Bashirian, S., Johnson, J., Soriano, V., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/507306 · Cited by 191
Self-citationDumond, J. B., Yeh, R. F., Patterson, K. B., Corbett, A. H., Jung, B. H., Rezk, N. L., Bridges, A. S., Stewart, P. W., Cohen, M. S., & Kashuba, A. D. (2007) · AIDS · doi:10.1097/qad.0b013e328270385a · Cited by 176
Intermittent Prophylaxis with Oral Truvada Protects Macaques from Rectal SHIV Infection
García-Lerma, J. G., Cong, M.-E., Mitchell, J., Youngpairoj, A. S., Zheng, Q., Masciotra, S., Martin, A., Kuklenyik, Z., Holder, A., Lipscomb, J., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000391 · Cited by 171
Self-citationCoca, S. G., & Perazella, M. A. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200212000-00011 · Cited by 168
Cassetti, I., Madruga, J. V. R., Suleiman, J. M. A. H., Etzel, A., Zhong, L., Cheng, A. K., Enejosa, J., & for the Study 903E Team (2007) · HIV Clinical Trials · doi:10.1310/hct0803-164 · Cited by 168
Denton, P. W., Krisko, J. F., Powell, D. A., Mathias, M., Kwak, Y. T., Martinez-Torres, F., Zou, W., Payne, D. A., Estes, J. D., & Garcia, J. V. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008829 · Cited by 167
Liu, A. Y., Vittinghoff, E., Sellmeyer, D. E., Irvin, R., Mulligan, K., Mayer, K., Thompson, M., Grant, R., Pathak, S., O'Hara, B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023688 · Cited by 160 · cited 1×
“Effects on BMD observed in this investigation have been published previously.(26) This study represents the largest safety database of US participants on oral daily PrEP to date.”
MethodSelf-citationMartin, J. N., Roland, M. E., Neilands, T. B., Krone, M. R., Bamberger, J. D., Kohn, R. P., Chesney, M. A., Franses, K., Kahn, J. O., Coates, T. J., et al. (2004) · AIDS · doi:10.1097/00002030-200403260-00010 · Cited by 154 · cited 1×
“The potential for behavioral risk compensation remains an open question, although risk compensation was observed neither in previous PrEP trials nor in open-label studies of postexposure prophylaxis.(35) PrEP will require ongoing engagement with the health care system to monitor adherence, potential HIV exposure, and…”
BackgroundAntiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals
Okwundu, C. I., & Okoromah, C. A. N. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007189.pub2 · Cited by 133
Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure
Rifkin, B. S., & Perazella, M. A. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.03.025 · Cited by 114
Underhill, K., Operario, D., Skeer, M. R., Mimiaga, M. J., & Mayer, K. H. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181e8efe4 · Cited by 101 · cited 1×
“PrEP will require ongoing engagement with the health care system to monitor adherence, potential HIV exposure, and the appropriateness of PrEP for each individual over time.(36) In conclusion, these data contribute important information for the development of clinical guidelines for PrEP among US MSM.”
BackgroundSelf-citationMayer, K. H., Mimiaga, M. J., Cohen, D., Grasso, C., Bill, R., VanDerwarker, R., & Fisher, A. (2008) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e318162afcb · Cited by 68
Self-citationFDA paves the way for pre-exposure HIV prophylaxis
Holmes, D. I. R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61235-5 · Cited by 64 · cited 1×
“The US Food and Drug Administration (FDA) recently approved the use of TDF/FTC as PrEP in July 2012.(9) Efficacy of oral TDF/FTC PrEP was demonstrated among MSM in several Latin American countries, South Africa, Thailand, and the United States,(10) although less than 10% of participants were enrolled at US sites.”
BackgroundTosini, W., Müller, P. F., Prazuck, T., Benabdelmoumen, G., Peyrouse, E., Christian, B., Quertainmont, Y., Bouvet, É., & Rabaud, C. (2010) · AIDS · doi:10.1097/qad.0b013e32833dfad1 · Cited by 52
Research works printed but not linked: 2
- 2011, Thirty years of HIV1981-2011., MMWR Morb Mortal Wkly Rep, 60, 689
- 2011, HIV surveillanceUnited States, 1981-2008., MMWR Morb Mortal Wkly Rep, 60, 65
Cited by
Sexually Transmitted Infections Treatment Guidelines, 2021
Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr7004a1 · Cited by 3,018
Sexually Transmitted Diseases Treatment Guidelines, 2010
(2011) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2011.04.006 · Cited by 2,076
Grant, R. M., Anderson, P. L., McMahan, V., Liu, A., Amico, K. R., Mehrotra, M., Hosek, S., Mosquera, C., Casapia, M., Montoya, O., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70847-3 · Cited by 1,208
Self-citationEffectiveness and safety of oral HIV preexposure prophylaxis for all populations
Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R., O’Reilly, K. R., Koechlin, F. M., Rodolph, M., Hodges-Mameletzis, I., & Grant, R. M. (2016) · AIDS · doi:10.1097/qad.0000000000001145 · Cited by 993
“Two studies randomized participants to receive immediate or delayed PrEP [13,43], and one study compared daily PrEP with both placebo and”
BackgroundMethodResultInfluentialSelf-citationUS Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., et al. (2019) · JAMA · doi:10.1001/jama.2019.6390 · Cited by 312
Metadata
- Authors
- Grohskopf, L. A., Chillag, K. L., Gvetadze, R., Liu, A. Y., Thompson, M., Mayer, K. H., Collins, B. M., Pathak, S. R., O'Hara, B., Ackers, M. L., Rose, C. E., Grant, R. M., Paxton, L. A., & Buchbinder, S. P.
- Affiliations
- Centers for Disease Control and Prevention (US)
- AIDS Research Consortium of Atlanta (US)
- Beth Israel Deaconess Medical Center (US)
- Northrop Grumman (United States) (US)
- Gladstone Institutes (US)
- Corresponding author
- Grohskopf, Lisa A.
- Chillag, Kata L.
- Ackers, Marta L.
- Paxton, Lynn A.
- ORCID
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2013-09-01
- Volume
- 64
- Issue
- 1
- Pages
- 79-86
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2331361632
- Cited by
- 172
- References
- 32
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 7 · 2023: 13 · 2022: 15 · 2021: 19 · 2020: 9 · 2019: 12 · 2018: 20 · 2017: 17 · 2016: 24 · 2015: 15 · 2014: 10 · 2013: 2
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAIDS Journal of Acquired Immune Deficiency Syndromes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (200-2003-03007, 200-2003-03003, 200-2004-09853)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Keywords
- tenofovir disoproxil fumarate, HIV prevention, pre-exposure prophylaxis, clinical safety, adverse events, medication adherence, back pain, renal safety, creatinine elevation, seroconversion, anal sex
- MeSH terms
- Tenofovir, Adenine, Adolescent, Boston, Double-Blind Method, Follow-Up Studies, Georgia, Humans, Male, Middle Aged, San Francisco, HIV Infections, Treatment Outcome, Drug Monitoring, Hypophosphatemia, HIV Seronegativity, Homosexuality, Male, CD4 Lymphocyte Count, Anti-HIV Agents, Organophosphonates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.